164 related articles for article (PubMed ID: 37045502)
21. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
22. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
23. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Madan M; Abbott JD; Lennon R; So DYF; MacDougall AM; McLaughlin MA; Murthy V; Saw J; Rihal C; Farkouh ME; Pereira NL; Goodman SG;
J Am Heart Assoc; 2022 Jun; 11(12):e024709. PubMed ID: 35699175
[TBL] [Abstract][Full Text] [Related]
24. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.
Nakamura M; Kadota K; Takahashi A; Kanda J; Anzai H; Ishii Y; Shibata Y; Yasaka Y; Takamisawa I; Yamaguchi J; Takeda Y; Harada A; Motohashi T; Iijima R; Uemura S; Murakami Y;
J Am Heart Assoc; 2020 May; 9(10):e015439. PubMed ID: 32394794
[TBL] [Abstract][Full Text] [Related]
25. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H
Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458
[TBL] [Abstract][Full Text] [Related]
26. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
[No Abstract] [Full Text] [Related]
27. Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y
Cavallari LH; Limdi NA; Beitelshees AL; Lee JC; Duarte JD; Franchi F; Tuteja S; Giri J; Empey PE; Kreutz RP; Skaar TC; Allen JM; Coons JC; Gong Y; McDonough CW; Stevenson JM; Thomas CD; Johnson JA; Stouffer GA; Angiolillo DJ; Lee CR;
Clin Pharmacol Ther; 2023 Mar; 113(3):615-623. PubMed ID: 36306392
[TBL] [Abstract][Full Text] [Related]
28. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
O'Donoghue ML; Murphy SA; Sabatine MS
Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
[TBL] [Abstract][Full Text] [Related]
29. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
30. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
31.
Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
[TBL] [Abstract][Full Text] [Related]
32. Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study.
D'Amario D; Galli M; Restivo A; Canonico F; Vergallo R; Migliaro S; Trani C; Burzotta F; Aurigemma C; Laborante R; Romagnoli E; Francese F; Ceccarelli I; Borovac JA; Angiolillo DJ; Tavazzi B; Leone AM; Crea F; Patti G; Porto I
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):190-200. PubMed ID: 38006237
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
[TBL] [Abstract][Full Text] [Related]
34. Tailored P2Y
Janssen PWA; Bergmeijer TO; Vos GA; Kelder JC; Qaderdan K; Godschalk TC; Breet NJ; Deneer VHM; Hackeng CM; Ten Berg JM
Eur J Clin Pharmacol; 2019 Sep; 75(9):1201-1210. PubMed ID: 31197411
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
Coons JC; Stevenson JM; Patel A; Smith AJC; Prebehalla L; Empey PE
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221143246. PubMed ID: 36503270
[TBL] [Abstract][Full Text] [Related]
36. Net adverse clinical events with P2Y
Cenko E; Manfrini O; Bugiardini R
Atherosclerosis; 2024 Mar; 390():117434. PubMed ID: 38233328
[No Abstract] [Full Text] [Related]
37. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
[TBL] [Abstract][Full Text] [Related]
38. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
39. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
40. CYP2C19 genotype-directed P
Stys TP; Gedela M; Gowda SN; Bares V; Fanta L; Petrasko M; Hajek C; Larson E; Stys AT
Indian Heart J; 2021; 73(3):281-288. PubMed ID: 34154743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
